dysbetalipoproteinemia

dysbetalipoproteinemia

 [dis-ba″tah-lip″o-pro″tēn-e´me-ah]
the accumulation of abnormal low-density lipoproteins (β-lipoproteins) in the blood.
familial dysbetalipoproteinemia familial hyperlipoproteinemia, type III.

fa·mil·i·al hy·per·lip·o·pro·te·in·e·mi·a type III

[MIM*107741]
hyperlipoproteinemia characterized by increased plasma levels of LDL, β-lipoproteins, pre-β-lipoproteins, cholesterol, phospholipids, and triglycerides; hypertriglyceridemia induced by a high carbohydrate diet, and glucose tolerance is abnormal; frequent eruptive xanthomas and atheromatosis, particularly coronary artery disease; biochemical defect lies in apolipoproteins. There are many varieties, one of which is caused by mutation in the APOE gene on chromosome 19q.

dysbetalipoproteinemia

/dys·be·ta·lipo·pro·tein·emia/ (-ba″tah-lip″o-pro″te-ne´me-ah)
1. the accumulation of abnormal β-lipoproteins in the blood.

familial dysbetalipoproteinemia  an inherited disorder of lipoprotein metabolism caused by interaction of a defect in apolipoprotein E with genetic and environmental factors causing hypertriglyceridemia; its phenotype is that of a type III hyperlipoproteinemia.

dysbetalipoproteinemia

[disbet′əlip′əprō′tinē′mē·ə]

dysbetalipoproteinemia

the accumulation of abnormal β-lipoproteins in the blood.
References in periodicals archive ?
Non denaturing polyacrolamide gradient gel electrophoresis for the diagnosis of dysbetalipoproteinemia.
Food and Drug Administration today approved the first generic version of Crestor (rosuvastatin calcium) tablets for the following uses: in combination with diet for the treatment of high triglycerides (hypertriglyceridemia) in adults; in combination with diet for treatment of patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia), a disorder associated with improper breakdown of cholesterol and triglycerides; either alone or in combination with other cholesterol treatment(s) for adult patients with homozygous familial hypercholesterolemia, a disorder associated with high low-density lipoprotein (LDL) cholesterol.
USPRwire, Fri Jun 13 2014] GlobalData's clinical trial report, "Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2014" provides data on the Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) clinical trial scenario.
The differential diagnosis of mixed hyperlipidemia also includes familial combined hyperlipidemia (FCHL), familial dysbetalipoproteinemia, and familial hypertriglyceridemia.
The hereditary types of hyperlipoproteinemia are familial lipoprotein lipase deficiency and/or apoprotein C-II deficiency (type I or V), familial hypercholesterolemia (type IIa or IIb), familial dysbetalipoproteinemia type III), familial hypertriglyceridemia (type IV), and combined hypercholesterolemia (type IIa, IIb, and/or IV) (table).
Remnant-like particle cholesterol levels in patients with dysbetalipoproteinemia or coronary artery disease.
However, other studies have reported premature CHD in hypertriglyceridemia, particularly when associated with hypertension or other lipid abnormalities characterized by small and apparently atherogenic VLDL and/or remnant particles as in familial combined hyperlipidemia and dysbetalipoproteinemia.
Simvastatin is indicated to: reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG); to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb); to reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia); to reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type lll hyperlipidemia); and to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.
5 mmol/L (400 mg/dL), in familial dysbetalipoproteinemia, or when there is abnormal VLDL composition.
Non-denaturing polyacrylamide gradient gel electrophoresis for the diagnosis of dysbetalipoproteinemia.
Dysbetalipoproteinemia (type III hyperlipoproteinemia) requires 2 copies of the binding defective APOE E2 allele.
Characterization of human very low density lipoproteins containing two electrophoretic populations: double pre-beta lipoproteinemia and primary dysbetalipoproteinemia.